In an interesting development in the field of rare disease therapeutics, Shionogi & Co., Ltd., and Maze Therapeutics, Inc. have sealed an exclusive worldwide license agreement for MZE001, a novel therapeutic candidate aimed at tackling Pompe disease.
Neurocrine Biosciences Inc. has initiated its phase 1 clinical study, marking a significant stride in the evaluation of NBI-1117567, an investigational small molecule, oral compound developed by Nxera Pharma.
Courtney Noah works in scientific affairs at BioIVT and after an amazing biology teacher in grade nine gave her a passion for science, she then followed the same teacher through her education.
Walgreens and Boehringer Ingelheim have joined forces in a move to enhance diversity and accessibility in clinical trials, aiming to make participation more inclusive and equitable.
Clerkenwell Health is proud to announce the launch of its foundation course for Psychedelic-Assisted Therapy, a comprehensive 30-hour program that brings together leading experts in the field.
Owlstone Medical, a global leader in Breath Biopsy for early disease detection and precision medicine, has announced a funding to the tune of $6.5 million.
In the heart of Montreal sits the non-profit organization Centech, a place that supports projects and startups with high growth potential – from conception right through to commercialization, which it says is thanks to a bold, collaborative, and passionate...
Last month, OSP was excited to write about One2Treat, a progressive startup specializing in digital health solutions, which has launched a forward-thinking approach aimed at tackling key challenges in the biopharma industry.
From a child's chemistry set given to her by her grandfather to watching Open University maths programs, Karen Ooms seemed destined for a career in science.
In a remarkable development, Front Line Medical Technologies Inc., an innovator in trauma care medical devices, has announced the attainment of CE marking for its COBRA-OS (Control of Bleeding, Resuscitation, Arterial Occlusion System).
In a major partnership aimed at accelerating research into Rett syndrome, a rare neurological disorder predominantly affecting girls, digital healthcare solutions company Vivalink, has joined forces with the Rett Syndrome Research Trust (RSRT).
Oncimmune Holdings plc, a prominent autoantibody profiling company catering to the pharmaceutical and biotechnology sectors, is expanding its horizons by delving into the realm of biomarkers for age-related diseases.
At CPhI North America, Quotient Sciences is looking forward to reconnecting with its customers and giving them a preview of how we are looking to expand Translational Pharmaceutics further within the US.
Kynos Therapeutics Ltd, based in Edinburgh, UK, focuses on developing small molecule kynurenine 3-monooxygenase (KMO) inhibitors for inflammatory disorders.
In a significant development for the multiple myeloma community, Menarini Stemline UK today welcomed the final draft guidance from the National Institute for Health and Care Excellence (NICE).
Earlier this week, Charles River Laboratories International, Inc. revealed its Alternative Methods Advancement Project (AMAP), which it said is a strong initiative aimed at changing drug discovery and development by exploring alternatives to animal testing.
On Monday, OSP published a story about AstraZeneca’s latest modeling analysis which highlighted major concerns about the future of chronic kidney disease (CKD) across eight countries.
During DCAT this year, CEO Gaston Salinas from Botanical Solution Inc., (BSI), sat down with Liza Laws, the senior editor of OSP and BPR to discuss his company’s pioneering work in revolutionizing vaccine adjuvant production.
Qinecsa Solutions (Qinecsa), a lead company in technology-driven end-to-end pharmacovigilance solutions has announced its acquisition of Insife ApS (Insife), a Danish-based firm specializing in innovative pharmacovigilance platforms.
Charles River Laboratories International, Inc. has unveiled its Alternative Methods Advancement Project (AMAP), a strong initiative aimed at changing drug discovery and development by exploring alternatives to animal testing.
In a recent discussion with Jan Vertommen, vice president and head of commercial development for the small molecules division at Lonza, key insights were shared regarding the pharmaceutical industry's current landscape and future trajectory.
Within the rapidly evolving landscape of decentralized clinical trials (DCTs), one critical challenge persists: the accurate monitoring of cough symptoms.
Michael Fronstin, global head of client partnership and commercialization at the company said the combination of Oracle’s life sciences expertise and platform technology help CROs win more business and run trials more efficiently.
AstraZeneca's latest modelling analysis, IMPACT CKD, presented at the 2024 ISN World Congress of Nephrology (WCN'24) in Buenos Aires, paints a concerning picture of the future of chronic kidney disease (CKD) across eight countries.
Bio Pharma Reporter and Outsourcing Pharma is back with our latest instalment of movers and shakers - breaking down all the key pharma industry appointments that you should know about. KBI Biopharma, Veranova and Kindeva Drug Delivery are among the companies...
In a groundbreaking revelation, a study conducted by RCSI University of Medicine and Health Sciences and Children’s Health Ireland has confirmed the safety and efficacy of a Cystic Fibrosis drug in newborns as young as four weeks old.
Beacon Biosignals made waves in the healthcare tech sector today with the announcement of FDA 510(k) clearance for a progressive machine learning software designed to change the analysis of sleep patterns.
In an exciting collaboration, modern mental health company, Clerkenwell Health, and Beckley Psytech, a clinical-stage biotechnology company, have launched a phase 2a study aimed at investigating a potential breakthrough treatment for alcohol use disorder...
From math hater to a leader in clinical data, it’s been a long journey for Jennifer Visser-Rogers, vice president for statistical research and consultancy at Phastar.
Yesterday (March 18) PureTech Health plc announced the completion of the acquisition of its founded entity, Karuna Therapeutics, Inc., by Bristol Myers Squibb for a staggering $14 billion.
Greater integration is to take place between the US and UK following an expansion says Cresset, a provider of integrated in-silico solutions for drug discovery.
International pharmaceutical firm Angelini Pharma has initiated a creative crowdsourcing campaign aimed at enhancing target identification in epilepsy, particularly focusing on drug-resistant phenotypes.
On March 7, Celadon Pharmaceuticals plc, a leading UK-based pharmaceutical company specializing in cannabis-based medicines, unveiled promising findings from an early economic analysis of its chronic pain clinical trial, dubbed CANPAIN.
Clerkenwell Health, a company that delivers clinical trials for the treatment of complex mental health volunteers for trials into the use of psychoactive medications for treating PTSD, is in search of 40 ex-military volunteers.
Form Bio and Ginkgo Bioworkshave joined forces in what they call a groundbreaking partnership aimed at advancing AAV gene therapy design and development.
By Progressive data analytics platform bioinformatics launched by Metabolon
Metabolon, Inc., a prominent figure in metabolomics solutions, has launched a seminal integrated bioinformatics platform, aiming to redefine metabolomics analysis in life sciences research.
Mandziuk is vice president, project management, eClinical Development & Delivery, at ICON and she says nothing could have prepared the health industry for the global impact the Covid pandemic has had.
Last week (February 22), it was announced a recent survey conducted jointly by Climedo and Siteworks has shed light on the perspectives of more than 65 primarily European-based study physicians.
Results from a phase 3 trial looking at treatment for primary biliary cholangitis (PBC) are 'genuinely exciting' and support the potential for seladelpar to raise the bar in treatment of the disease.
In the fast-evolving landscape of healthcare and pharmaceuticals, the role of technology, particularly artificial intelligence (AI), is becoming increasingly prominent.
Jane Kendrew changed paths after a year of her first degree knowing it was exactly the right way for her. She left university with a first class honours degree and turned down the offer of a PhD to start her dream job as a research scientist.